- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Stableford Capital II LLC Acquires New Shares in Biogen Inc.
Biotechnology firm sees new institutional investor take stake
Mar. 27, 2026 at 10:04am
Got story updates? Submit your updates here. ›
Stableford Capital II LLC, an investment firm, acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to a filing with the Securities and Exchange Commission. The firm purchased 6,914 shares of the biotechnology company's stock, valued at approximately $1,217,000.
Why it matters
Biogen is a major player in the biotechnology industry, known for its therapies for multiple sclerosis and other neurological conditions. The acquisition of new shares by Stableford Capital II LLC suggests continued investor interest in the company despite recent challenges.
The details
Stableford Capital II LLC acquired the 6,914 shares of Biogen stock during the fourth quarter of 2025. The shares were valued at approximately $1,217,000. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in Biogen, with State Street Corp and Invesco Ltd. among the larger shareholders.
- Stableford Capital II LLC acquired the new Biogen shares during the 4th quarter of 2025.
The players
Stableford Capital II LLC
An investment firm that acquired a new position in shares of Biogen Inc.
Biogen Inc.
A multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases.
State Street Corp
A large institutional investor that owns shares of Biogen.
Invesco Ltd.
A major investment management firm that holds a stake in Biogen.
The takeaway
Biogen continues to attract interest from institutional investors despite recent challenges, underscoring the company's importance in the biotechnology industry and its potential for future growth.
